FDA Cardiac Arrest Alert: 135 Batches Of Medication Recalled

According to official reports, 135 batches of capsules are being recalled from consumers due to concerns about the potential risk of triggering cardiac arrest from the defective medication.

Glenmark Pharmaceuticals began the recall of 114 batches of potassium chloride extended-release capsules last week, while American Health Packaging, on behalf of BluePoint Laboratories, recalled 21 batches of the same capsules.

LOOK:

The decision to recall the capsules was made after problems were found with the way they dissolve, which could potentially lead to high levels of potassium and increase the risk of hyperkalemia.

This information was shared in notifications released by the US Food and Drug Administration on behalf of the companies.

The companies have warned that elevated potassium levels, which can cause hyperkalemia, may lead to irregular heartbeats and pose a risk of cardiac arrest.

Glenmark initiated its recall on a Monday, with BluePoint doing the same the following day. Both companies’ capsules are manufactured by Glenmark, according to the Miami Herald.

As stated in both recalls, “To date, the firm has not received any reports of hyperkalemia or serious adverse events from spontaneous sources related to this recall.”

These capsules are designed for patients who have low potassium levels, known as hypokalemia, and are usually sold in bottles of 100 and 500.

The FDA has released the list of recalled batch numbers for Glenmark and BluePoint on its official website.

Following the recall, the companies have recommended that individuals with the affected Potassium Chloride Extended-Release Capsules consult their physician or healthcare provider before stopping use of the product.

Furthermore, consumers are encouraged to contact their healthcare provider if they have experienced any problems related to the consumption or use of this medication.

ICYMI: Biden Camp Responds to SCOTUS Immunity Ruling with Unhinged Statement Attacking Trump